Propafenone Hydrochloride Tablets

Effects and efficacy:
Propafenone hydrochloride tablets are mainly used to treat paroxysmal ventricular tachycardia, paroxysmal supraventricular tachycardia (including those with preexcitation syndrome), and premature contractions. This product can also be used for symptomatic supraventricular tachycardia, such as atrioventricular junctional tachycardia, WPW syndrome combined with supraventricular tachycardia or paroxysmal atrial fibrillation, and ventricular tachycardia that requires treatment or is fatal as determined by a physician.
Usage and dosage:
Because propafenone hydrochloride tablets have local anesthetic effects and can cause numbness in the mouth and tongue, it is advisable to swallow the whole tablet with drinks or food after meals, and do not chew it. 50mg and 100mg oral: 100~200mg once, 3~4 times a day. Therapeutic dose, 300~900mg a day, taken in 4~6 times; maintenance dose, 300~600mg a day, taken in 2~4 times. 150mg Under cardiac monitoring, including ECG monitoring and repeated blood pressure measurement (stable period), formulate individual maintenance doses, or follow doctor’s advice. The recommended starting and maintenance doses for patients weighing ≥70 kg are: 450~600 mg per day, divided into three doses, which can be increased to 900 mg per day divided into three doses as needed; the dose for patients weighing <70 kg should be reduced accordingly. Only in individual cases and under strict cardiac monitoring can this dose be exceeded. The dose of propafenone must be increased with caution at the beginning of treatment, and small increases are required, especially in the elderly, patients with significant myocardial damage, hepatic insufficiency or renal insufficiency, and plasma concentration monitoring of the drug may be required. The first dose increase should be 3~4 days after the initial medication. Patients with ventricular arrhythmias should undergo close ECG monitoring when starting propafenone treatment, and treatment can only be started under conditions where cardiac emergency facilities are available and monitoring is ensured. Regular follow-up during treatment (e.g., standard ECG every month, dynamic ECG every 3 months, and exercise ECG if necessary). If there are changes in the electrocardiogram, such as QRS or QT interval prolongation of more than 25%, PR interval prolongation of more than 50%, QT greater than 500ms, arrhythmia aggravation or increased frequency of attacks, the doctor will decide whether to continue treatment. Patients with relative left ventricular dysfunction (left ventricular ejection fraction <35%) or organic cardiomyopathy should be particularly cautious when starting treatment, and the dose should be increased in small amounts. It is recommended to delay the increase in dose for such patients until the plasma concentration is stable (usually 5 to 8 days) to reduce the risk of propafenone proarrhythmia in the early stage of treatment.
Adverse reactions:
The following adverse reactions may occur with propafenone hydrochloride tablets. Cardiovascular system: Q-T interval prolongation, mild prolongation of P-R interval, QRS time prolongation, cardiac conduction abnormalities (including sinoatrial block, atrioventricular block, intraventricular block), palpitations, bradycardia, sinus bradycardia, tachycardia, ventricular tachycardia, atrial flutter, arrhythmia, hypotension (including orthostatic hypotension). After the launch, there are also reports of ventricular fibrillation, heart failure, and slow heart rate. Respiratory system: dyspnea. Urogenital system: erectile dysfunction. After the launch, there are also reports of decreased sperm count (reversible after discontinuation of the drug). Immune system: hypersensitivity reactions and lupus-like syndrome have been reported after the launch. Nervous system: sleep disorders, headaches, dizziness, syncope, ataxia, paresthesia, vertigo. After the launch, there are also reports of confusion, syncope, extrapyramidal symptoms, and hyperactivity. Mental system: anxiety, nightmares. Liver: increased aspartate aminotransferase, increased alanine aminotransferase, increased gamma-glutamyl transferase, and increased alkaline phosphatase. After the launch, there are also reports of hepatocellular damage, cholestasis, hepatitis, and jaundice. Gastrointestinal tract: numbness of the tongue and lips (probably due to its local anesthetic effect), loss of appetite, taste disorders, abdominal pain, vomiting, nausea, diarrhea, constipation, dry mouth, abdominal distension, and flatulence. After the launch, there are also reports of retching and gastrointestinal disorders. Blood: thrombocytopenia. There are also reports of agranulocytopenia, leukocytopenia, and granulocytopenia after the product is marketed. Skin: urticaria, itching, rash, erythema. Eyes: food blurring. Others: chest pain, weakness, fatigue, fever.
Drug contraindications:
Allergic to this product, do not drink alcohol, use with caution, use with caution in liver and kidney dysfunction, use with caution during pregnancy, use with caution during lactation